Clovis submits application to EMA to expand use of Rubraca to include maintenance treatment for women with recurrent ovarian cancer

|About: Clovis Oncology (CLVS)|By:, SA News Editor

Clovis Oncology (NASDAQ:CLVS) submits a regulatory application to the European Medicines Agency (EMA), as part of a type II variation seeking to expand the marketing authorization for Rubraca (rucaparib) to include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy.

Based on the timing of this submission, the company anticipates an opinion from the Committee for Medicinal Products for Human Use (CHMP) by end of 2018.

Subscribe for full text news in your inbox